Logo do repositório
 
Publicação

Pharmacogenomics and substance use disorders in Portugal: bridging the gap between scientific evidence and drug labelling

2026-05-29Documento de conferência Acesso aberto
Ver registo simples
dc.contributor.authorTorres, Ana
dc.contributor.authorRibeiro, Ana
dc.contributor.authorAntónio, Jéssica
dc.contributor.authorSantos, Marlene
dc.contributor.authorSantos, Marlene
dc.date.accessioned2026-07-28T09:13:17Z
dc.date.available2026-07-28T09:13:17Z
dc.date.issued2026-05-29
dc.description.abstractSubstance use represent a major global public health burden requiring pharmacological interventions grounded in robust scientific evidence (1). Pharmacogenomics offers a critical framework for personalised medicine by tailoring therapies to indi-vidual genetic profiles an approach particularly rele-vant in addiction treatment (2). To evaluate the degree of alignment between current pharmacogenomic evidence and regulatory documents, namely Summaries of Product Characteristics (SPCs) and Patient Information Leaflets (PILs), for drugs classified under the WHO N07B group and bupropion (N06AX). A structured review was conducted for drugs spanning ATC subgroups: N07BA (varenicline, cytisinicline, nicotine); N07BB (disulfiram, naltrexone, nalmefene); N07BC (methadone, buprenorphine, buprenorphine/naloxone); and bupropion (N06AX) (3). SPCs and PILs were retrieved from Infomed (4). Pharmacogenomic evidence was systematically sourced from CPIC guidelines and PharmGKB annotations (5). For each drug, the presence, accuracy, and completeness of pharmacogenomic information in regulatory documents were assessed against these reference databases, with particular focus on clinically actionable genedrug interactions involving variants such as CYP2D6, ADH1B, ALDH2, and CHRNA5. Genetic variants including CYP2D6, ADH1B, ALDH2, and CHRNA5 are established modulators of drug metabolism and dependence susceptibility across this therapeutic class. Nevertheless, SPCs and PILs for the ma-jority of reviewed drugs contain absent or outdated pharmacogenomic information, with poor alignment to current CPIC and PharmGKB recommendations. Better incorporation of validated genetic data into SPCs and PILs would strengthen clinical decision making, and support treatment personalisation, in the management of substance use disorders.eng
dc.identifier.citationTorres, A., Ribeiro, A., António, J., & Santos, M. (2026). Pharmacogenomics and substance use disorders in Portugal: Bridging the gap between scientific evidence and drug labelling. Book of Abstracts of the 8th Meeting on Medicinal Biotechnology, 53. https://edicoes.ipp.pt/index.php/books/catalog/book/251
dc.identifier.doi10.26537/ed.p.porto.251
dc.identifier.isbn978-989-9226-20-3
dc.identifier.urihttp://hdl.handle.net/10400.22/32618
dc.language.isoeng
dc.peerreviewedyes
dc.publisherPolitema
dc.relation.hasversionhttps://edicoes.ipp.pt/index.php/books/catalog/book/251
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectPharmacogenomics
dc.subjectDrugs of abuse
dc.subjectGenetic variants
dc.titlePharmacogenomics and substance use disorders in Portugal: bridging the gap between scientific evidence and drug labellingeng
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferenceDate2026-05-29
oaire.citation.conferencePlacePorto
oaire.citation.endPage53
oaire.citation.startPage53
oaire.citation.titleBook of Abstracts of the 8th Meeting on Medicinal Biotechnology
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameSantos
person.givenNameMarlene
person.identifier1508370
person.identifier.ciencia-id8311-B967-31C4
person.identifier.orcid0000-0001-5020-5942
person.identifier.scopus-author-id57110502000
relation.isAuthorOfPublication8ce9ee39-a4c6-46ae-99e2-49397b550f1b
relation.isAuthorOfPublication.latestForDiscovery8ce9ee39-a4c6-46ae-99e2-49397b550f1b

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
POSTER_Marlene Santos1.pdf
Tamanho:
1.21 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

ESS - CISA/LAQV Requimte - Posters apresentados em eventos científicos
ESS - FAR - Posters apresentados em eventos científicos